We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Aureus Licenses AurSCOPE ADME/DDI and hERG Knowledge Databases to Siena
News

Aureus Licenses AurSCOPE ADME/DDI and hERG Knowledge Databases to Siena

Aureus Licenses AurSCOPE ADME/DDI and hERG Knowledge Databases to Siena
News

Aureus Licenses AurSCOPE ADME/DDI and hERG Knowledge Databases to Siena

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Aureus Licenses AurSCOPE ADME/DDI and hERG Knowledge Databases to Siena"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Aureus Pharma has announced that Siena Biotech has licensed both AurSCOPE ADME/Drug-Drug Interaction and hERG knowledge databases for its internal research work. 

Better understanding of the ADME-Tox properties of potential drug candidates is an integral part of the pharmaceutical industry’s current strategy to reduce the attrition rate in bringing new drugs to the market.

Aureus’ ADME/DDI and hERG knowledge databases contain detailed data including metabolism, inhibition, drug-drug interactions and pharmacokinetics which can help assess the safety of a potential pharmaceutical candidate.

"Aureus Pharma’s knowledge databases on ADME and hERG provide Siena Biotech researchers access to important data to assess ADME properties early in the drug discovery process and complement our in-house knowledge-based drug design platform," commented Siena Biotech’s Dr. Graeme M. Robertson, Vice President Therapeutic Research.

"We are very pleased that Siena Biotech has chosen Aureus Pharma's solutions," said Dr. Andre Michel, CEO of Aureus Pharma.

"Having access to the data in our ADME & hERG knowledge databases allows scientists to save valuable research time by using this prior knowledge and improve prioritization in drug discovery process."

Advertisement